TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TKPHF.PK) and AC
Immune SA (ACIU) Monday said they have signed license agreement for Immune's
active immunotherapies including ACI-24.060 for the treatment of Alzheimer's
disease.

As per the terms of the agreement, Takeda will receive an exclusive option to
license global rights to ACI-24.060, designed to delay or slow Alzheimer's
disease progression.

AC Immune will receive an upfront payment of $100 million and be eligible to
receive an option exercise fee and additional milestone payments of up to about
$2.1 billion. Upon commercialization, AC Immune will be entitled to receive
tiered double-digit royalties on sales.

ACI-24.060 is currently being investigated in the ABATE Phase 1b/2 trial in
subjects with prodromal Alzheimer's disease and in adults with Down syndrome.
After completing ABATE trial by AC Immune, Takeda would conduct further clinical
developments of ACI-24.060. Takeda would also be responsible for all global
regulatory activities as well as worldwide commercialization.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX